Douglas Forsyth, Director at Inhibrx Biosciences, Inc. (INBX), bought 2,500 shares at $114.65 ($287K) on 2026-09-08, disclosed to the SEC on 2026-09-08.
Open-market purchase of $287k INBX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| NCV | SELL | 2014-06-27 | $159K | — | Filing → |
| NIE | BUY | 2008-09-22 | $151K | — | Filing → |
| NIE | BUY | 2007-08-21 | $108K | — | Filing → |